ATE510822T1 - Kaliumkanalinhibitoren - Google Patents

Kaliumkanalinhibitoren

Info

Publication number
ATE510822T1
ATE510822T1 AT06816997T AT06816997T ATE510822T1 AT E510822 T1 ATE510822 T1 AT E510822T1 AT 06816997 T AT06816997 T AT 06816997T AT 06816997 T AT06816997 T AT 06816997T AT E510822 T1 ATE510822 T1 AT E510822T1
Authority
AT
Austria
Prior art keywords
potassium channel
channel inhibitors
inhibitors
compounds
relates
Prior art date
Application number
AT06816997T
Other languages
English (en)
Inventor
Scott Wolkenberg
Mark Bilodeau
Brad M Nolt
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE510822T1 publication Critical patent/ATE510822T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Heads (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06816997T 2005-10-21 2006-10-17 Kaliumkanalinhibitoren ATE510822T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72907805P 2005-10-21 2005-10-21
PCT/US2006/040409 WO2007050347A1 (en) 2005-10-21 2006-10-17 Potassium channel inhibitors

Publications (1)

Publication Number Publication Date
ATE510822T1 true ATE510822T1 (de) 2011-06-15

Family

ID=37845325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06816997T ATE510822T1 (de) 2005-10-21 2006-10-17 Kaliumkanalinhibitoren

Country Status (15)

Country Link
US (1) US7973059B2 (de)
EP (1) EP1951672B1 (de)
JP (1) JP4931930B2 (de)
KR (1) KR20080057296A (de)
CN (1) CN101291910A (de)
AT (1) ATE510822T1 (de)
AU (1) AU2006306541B2 (de)
BR (1) BRPI0617655A2 (de)
CA (1) CA2626402C (de)
IL (1) IL190730A0 (de)
NO (1) NO20082298L (de)
NZ (1) NZ567000A (de)
RU (1) RU2008119994A (de)
WO (1) WO2007050347A1 (de)
ZA (1) ZA200802848B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3003038T3 (en) 2009-03-18 2025-03-10 Incarda Therapeutics Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2017136421A1 (en) 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
WO2019222093A1 (en) 2018-05-14 2019-11-21 Ariad Pharmaceuticals, Inc. Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
KR20250171439A (ko) 2019-08-01 2025-12-08 인카다 테라퓨틱스, 인크. 항부정맥 제제
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005269505B2 (en) * 2004-07-29 2011-06-16 Merck Sharp & Dohme Corp. Potassium channel inhibitors
EP1781635B1 (de) * 2004-07-29 2012-06-13 Merck Sharp & Dohme Corp. Kaliumkanalinhibitoren
WO2007050348A2 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors

Also Published As

Publication number Publication date
JP2009512702A (ja) 2009-03-26
AU2006306541A1 (en) 2007-05-03
CN101291910A (zh) 2008-10-22
ZA200802848B (en) 2009-01-28
EP1951672A1 (de) 2008-08-06
KR20080057296A (ko) 2008-06-24
AU2006306541B2 (en) 2011-07-14
US7973059B2 (en) 2011-07-05
CA2626402C (en) 2011-02-15
BRPI0617655A2 (pt) 2016-08-23
CA2626402A1 (en) 2007-05-03
RU2008119994A (ru) 2009-12-10
US20090042944A1 (en) 2009-02-12
JP4931930B2 (ja) 2012-05-16
WO2007050347A1 (en) 2007-05-03
IL190730A0 (en) 2008-11-03
NO20082298L (no) 2008-07-17
NZ567000A (en) 2010-03-26
EP1951672B1 (de) 2011-05-25

Similar Documents

Publication Publication Date Title
NO20082298L (no) Kaliumkanalinhibitorer
WO2006015159A3 (en) Potassium channel inhibitors
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
WO2005030129A3 (en) Quinoline potassium channel inhibitors
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
NO20081636L (no) FAP - inhibitorer
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
LTPA2016036I1 (lt) Nitrokatechnolio dariniai, kaip COMT inhibitoriai
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
CY1115713T1 (el) Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες
EA200701918A1 (ru) Белок липокалин
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
ZA200709763B (en) 2,4-diamino-pyrimidines used as aurora inhibitors
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
EA201170703A1 (ru) Производные адамантилбензамида
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
WO2007050348A3 (en) Potassium channel inhibitors
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
WO2005030792A3 (en) Quinoline potassium channel inhibitors
DE502006005053D1 (de) Spritzbare akustikmassen
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties